New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
08:58 EDTDDD, CTSH, OMER, DATA, VJET, MRK, XONE, SSYS, RL, COCOOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Merck (MRK), up 1.6%... Ralph Lauren (RL), up 7%... Tableau Software (DATA), up 12%... Corinthian Colleges (COCO), up 2%. ALSO HIGHER: Omeros (OMER), up 11% after granted fast track designation to OMS824 by FDA. DOWN AFTER EARNINGS: Allergan (AGN), down xx%... Cognizant (CTSH), down 5%. ALSO LOWER: 3D Systems (DDD), down 15% after lowering FY13 EPS view, guiding FY14 below estimates. Peers Stratasys (SSYS), down 7.5%, ExOne (XONE), down 8%, and Voxeljet (VJET), down 7%, lower as well.
News For DDD;RL;SSYS;XONE;MRK;VJET;DATA;OMER;CTSH;COCO From The Last 14 Days
Check below for free stories on DDD;RL;SSYS;XONE;MRK;VJET;DATA;OMER;CTSH;COCO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
08:32 EDTMRKMerck initiates Phase 3 study of Letermovir
Subscribe for More Information
July 23, 2014
10:19 EDTDDD3D Systems calls active on renewed takeover speculation
Subscribe for More Information
09:59 EDTDDDRumor: 3D Systems strength attributed to renewed takeover speculation
Subscribe for More Information
July 22, 2014
06:37 EDTVJET, SSYS, DDDPiper recommends buying 3D space following pullback
Piper Jaffray recommends using the recent weakness in shares of 3D printing companies as a buying opportunity, saying its Q2 reseller/industry survey yielded favorable feedback. The firm has Overweight ratings on 3D Systems (DDD), Materialise (MTLS), Materialise (MTLS), Proto Labs (PRLB) and Stratasys (SSYS). It has a Neutral rating on Voxeljet (VJET).
July 21, 2014
10:32 EDTCOCOCorinthian Colleges confirms appointment of independent monitor
Subscribe for More Information
08:11 EDTDATATableau risk/reward favorable, says Morgan Stanley
Subscribe for More Information
07:21 EDTMRKGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
06:43 EDTMRKGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 20, 2014
15:51 EDTCOCOEducation Department names team to monitor Corinthian Colleges
Subscribe for More Information
July 18, 2014
10:03 EDTDATAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
July 17, 2014
19:22 EDTDATATableau initiated with an Outperform at BMO Capital
Subscribe for More Information
July 16, 2014
06:26 EDTMRKBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
11:13 EDTMRKPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
10:00 EDTSSYSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:59 EDTCOCOApollo Education discloses new Department of Education review
Subscribe for More Information
09:07 EDTSSYSStratasys initiated with an Outperform at Cowen
Subscribe for More Information
08:11 EDTMRKMerck looks to revive livestock drug Zilmax, WSJ says
Merck has been preparing to conduct a large-scale study this summer to evaluate the safety of its Zilmax feed additive, which the company pulled from the U.S. market last year over concerns in the beef industry that the drug made it difficult for some animals to walk, reported The Wall Street Journal. Reference Link
07:35 EDTMRKPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
July 14, 2014
07:58 EDTSSYSMakerBot, Home Depot to bring MakerBot 3D printers to select stores
MakerBot, a subsidiary of Stratasys (SSYS), and The Home Depot (HD) announce a collaboration to bring MakerBot Replicator Desktop 3D Printers to customers on homedepot.com/makerbot and in 12 Home Depot stores in California, Illinois and New York beginning July 14. This is the first time The Home Depot has offered 3D printers for sale in its stores and will be a pilot program for MakerBot and The Home Depot.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use